Amy Paterson, Medical Analyst at GlobalData states, “Medtronic’s Sphere-9 launched at a lower price than Boston Scientific’s ...

J&J’s 2025 results will be the launching point for its guidance of 5%-7% revenue growth for 2025-30, which is still well ...

All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Johnson & Johnson’s latest earnings bested Wall Street estimates, as the company braces for one of its top-selling medicines ...

Analysts expect a profit per share of $2.02, which is a decline of 11.8% from the prior year period. The consensus revenue ...

Medtronic CEO Geoff Martha discusses innovations such as pulse field ablation, renal denervation, DBS, TAVR, diabetes tech ...

Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Johnson & Johnson ...

Johnson & Johnson has announced a temporarily pause in the rollout of its Varipulse heart device in the United States as it ...